| 靶点: |
CaSR;IC50: 0.39 μM (Inositol phosphate) |
| 体内研究: |
Calhex 231 (4.07 mg/kg (10 μmol/kg);腹腔注射;每天;持续 12 周;雄性 Wistar 大鼠) 处理可改善 1 型糖尿病模型 (T1D) 大鼠的糖尿病心肌纤维化。 |
| 参考文献: |
1. Christophe Petrel, et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem. 2003 Dec 5;278(49):49487-94. 2. Petrel C1, et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem. 2003 Dec 5;278(49):49487-94. 3. Yan Lei, et al. The Calcilytic Drug Calhex-231 Ameliorates Vascular Hyporesponsiveness in Traumatic Hemorrhagic Shock by Inhibiting Oxidative Stress and miR-208a-Mediated Mitochondrial Fission. Oxid Med Cell Longev. 2020 Dec 3:2020:4132785. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.255 ml |
11.276 ml |
22.552 ml |
| 5 mM |
0.451 ml |
2.255 ml |
4.51 ml |
| 10 mM |
0.226 ml |
1.128 ml |
2.255 ml |
| 50 mM |
0.045 ml |
0.226 ml |
0.451 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |